



## Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

February 26, 2024

WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in the TD Cowen 44<sup>th</sup> Annual Health Care Conference.

Cameron Turtle, Chief Executive Officer, will participate in the Inflammation & Immunology Corporate Panel Discussion on Tuesday, March 5, 2024, at 2:10 p.m. Eastern time.

To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at [ir.spyre.com](http://ir.spyre.com). An archive of the webcast will be available for replay for 30 days following the end of the conference.

### About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting  $\alpha 4\beta 7$ , TL1A, and IL-23. For more information, visit Spyre's website at [www.spyre.com](http://www.spyre.com).

Follow Spyre Therapeutics on social media: [@spyretx](https://twitter.com/spyretx) and LinkedIn

#### For Investors :

Eric McIntyre  
VP of Finance and Investor Relations  
Spyre Therapeutics  
[Eric.mcintyre@spyre.com](mailto:Eric.mcintyre@spyre.com)

#### For Media :

Peg Rusconi  
[Peg.rusconi@vergescientific.com](mailto:Peg.rusconi@vergescientific.com)

SOURCE Spyre Therapeutics, Inc.